Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
about
Timely and optimal treatment of patients with STEMIPeriprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventionsAntiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary InterventionsWhat Could be Changed in the 2012 Taiwan ST-Segment Elevation Myocardial Infarction Guideline?The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD studyCritical appraisal of ticagrelor in the management of acute coronary syndromeNew antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesEfficacy and Safety of Novel Oral P2Y12 Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis.Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysisA Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients.Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers.Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorMortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC RegistryAlmanac 2011: Acute Coronary Syndromes. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry).Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis.Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes.Ticagrelor: a review of its use in the management of acute coronary syndromes.The evolution of antiplatelet therapy in cardiovascular disease.Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.Clinical effects and outcomes with new P2Y12 inhibitors in ACS.Emerging therapies for acute coronary syndromesAntiplatelet options for secondary prevention in acute coronary syndromes.Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.Antiplatelet therapy in acute coronary syndromes.P2Y12 platelet inhibition in clinical practice.A comprehensive comparative review of adenosine diphosphate receptor antagonists.InforMatrix: ADP antagonists in acute coronary syndromes.Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment.Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
P2860
Q22251044-8ECA8BCD-98CB-4920-97EB-9BE1505E0DA5Q26740181-D0692F4D-7198-4A6D-8290-E43CBA539F5BQ26777116-FC9F4394-9660-4C54-9259-B4D49A6A7FEAQ28468713-CA3129E9-D33F-4CD6-8F49-8BDE6F4E401EQ34510681-98802C54-D178-44F5-BA72-2BFD609A7207Q34805121-0F5E71BF-26FC-4DF2-8EAF-E3F83E277490Q35126038-43F443E8-3472-4A08-A8B9-E95AF2D4F6F2Q35660767-35B6B169-9B0B-4093-925F-420E3F76E5CCQ35752611-72599AAF-08FF-4814-9C76-909F5F932FB5Q36237726-14EDB0D2-BBF4-473D-B7CA-26219947716AQ36337254-D5B66B3C-B5E0-455C-BA05-7C9D8ACEECEEQ36363183-8DD0FED2-9E68-4E4E-8222-C771C47E6011Q36723867-26903B49-2C82-4C5F-B4FE-CCCECBF87574Q36807413-10E641A8-C823-4213-9B43-25187F30662DQ36833637-003B4190-AAA7-4F59-BF79-0B372B103EABQ37066826-819E5C97-AA65-4213-A221-74C31F876500Q37076189-87D66328-489C-49A9-8019-8DBA125A7287Q37187636-09C45612-58E1-4166-8B20-435D3771BED9Q37240704-F8E1FB3A-79BD-4959-9628-B9A8A8950723Q37403998-6057E8F8-4291-4229-8998-BAFAA278B50DQ37668119-AC4CC568-348A-4BCA-AF7B-19D36C85DB17Q37875063-A83DFF18-4EE2-425A-82A2-A838DA3B8DC2Q37900470-08EA1771-B95A-4233-B483-E8E4C1609819Q37907902-538EFB9F-8A28-4FA0-B147-62036B957C07Q37914924-290D49B7-1A12-483F-88FC-F2F89DCC1028Q37923966-51360F04-6E24-4A73-92FB-82176781ED53Q37927149-1E675E32-4F28-4109-800B-03F907A7E4CBQ37949587-13C351EF-0560-486D-85D0-893F36A8F4FDQ37953465-96CC7C3A-18D6-491B-8B52-5F6B044D9E10Q37959155-5D890ECB-26EA-40A0-9F25-A790736DECA5Q37965609-9D3C2776-ED7D-48DB-AD5E-7DB2B977B420Q37969927-4AC54B02-0BDD-47E4-A687-F38BF9AA9CF8Q37973114-E5990201-15C0-4406-8DAF-FF26F51F9081Q37973397-A6156F5B-7C11-4D32-99E7-5C8B7E20061FQ37984773-57D4ACD8-5E2A-49D0-8B9D-9F38E01C28EAQ37990848-44288AED-3B3C-4476-BF6D-2A919F6003F4Q37997963-84F34D2A-28DC-42F8-A912-2949D65D40C1Q38005621-A5F923F9-A938-4C2B-A865-950EDB16D0EFQ38007860-CE42EFE4-6141-44E2-80CA-4B80D41AB410Q38008466-EDEA7E2A-E649-4683-A732-3903EA5EBE52
P2860
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Ticagrelor versus clopidogrel ...... LATO) trial subgroup analysis.
@en
type
label
Ticagrelor versus clopidogrel ...... LATO) trial subgroup analysis.
@en
prefLabel
Ticagrelor versus clopidogrel ...... LATO) trial subgroup analysis.
@en
P2093
P50
P1433
P1476
Ticagrelor versus clopidogrel ...... LATO) trial subgroup analysis.
@en
P2093
Ariel Finkelstein
Christopher P Cannon
Diego Ardissino
Hugo Katus
Jan Kilhamn
PLATO Study Group
Richard C Becker
Steen Husted
Stefan James
Sylvia Olofsson
P304
P356
10.1161/CIRCULATIONAHA.109.927582
P407
P577
2010-11-08T00:00:00Z